GobioLab Completes Dosing in Global Phase 1 Clinical Trial of Microbiome New Drug
Completion of Dosing for Autoimmune Disease Treatment New Drug KBLP-001 in Australian Phase 1 Clinical Trial
Targeting KOSDAQ Market Listing Within the Year
[Asia Economy Reporter Eunmo Koo] Microbiome specialist company GobioLab announced on the 10th that it has completed the final dosing of the Phase 1 clinical trial of the autoimmune disease treatment new drug 'KBLP-001' in Australia. The Phase 1 clinical trial of KBLP-001 is the first case of a microbiome new drug in Korea.
KBLP-001 is a new drug candidate selected from GobioLab's proprietary microbiome library (strain bank). It has proven efficacy through various autoimmune disease animal model tests such as atopic dermatitis and inflammatory bowel disease, and based on this, it is accelerating global clinical trials.
A GobioLab official stated, “The trial to confirm the safety, tolerability, and pharmacokinetics of KBLP-001 has been successfully completed,” and added, “Preparations for rapid entry into Phase 2 clinical trials are progressing smoothly based on additional analysis and results.” The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) this year for proceeding with Phase 2 clinical trials based on the results of this clinical trial.
GobioLab is also preparing global clinical trials for two or more new projects besides KBLP-001. The company announced that it plans to apply for the Phase 1 clinical trial in Australia for 'KBLP-002' (autoimmune disease) within the first quarter.
Hot Picks Today
While Samsung Falters, China Rises: "Chinese DRAM" Turns a Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
GobioLab CEO Kwangpyo Ko said, “With the successful completion of the Phase 1 clinical trial of KBLP-001 and the clinical entry of additional pipelines, we plan to strengthen GobioLab's core competitiveness,” and added, “We are actively pursuing partnerships with global companies to maximize the value of our research and development achievements and aim to enter the KOSDAQ market within this year.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
